American Hemp Protection Act of 2025
Summary
HR6209 is an early-stage bill to repeal scheduled 2026 federal controls on hemp, restoring the 2018 Farm Bill's definition. The bill has zero funding attached, no committee movement in 5 months, and minimal near-term probability of passage. Real market data shows cannabis stocks (TLRY, CGC, SNDL) declining 10-14% in the last week, unrelated to this bill's stalled status.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6209 is stalled in committee with 3 cosponsors after 5 months—very low probability of passage in the 119th Congress.
- 2.The bill authorizes $0 in spending; it is purely deregulatory—repealing a scheduled tightening of hemp product definitions.
- 3.Cannabis stocks (TLRY, CGC, SNDL) have declined 10-14% in the last week, unrelated to this bill's lack of progress.
- 4.If passed, the bill preserves the current legal market for hemp-derived cannabinoids but does not expand it—limited revenue upside for publicly traded companies.
- 5.The scheduled November 12, 2026 regulatory tightening remains the default unless this bill or similar legislation advances—a deadline that is 18 months away.
Market Implications
No near-term market impact. This bill is dead in the water for the 119th Congress based on action history. The real market data shows marijuana and hemp stocks (TLRY $6.14, CGC $1.09, SNDL $1.32) trading at or near their 52-week lows, reflecting sector-wide headwinds (regulatory uncertainty, state-level dynamics, capital constraints) rather than any pending legislative relief. The November 2026 regulatory deadline is the only concrete catalyst on the horizon, and it currently favors bearish positioning for hemp-exposed companies since repeal of that deadline requires legislative action that has not materialized.
Full Analysis
On November 20, 2025, Rep. Mace (R-SC) introduced HR6209, the American Hemp Protection Act of 2025. The bill targets section 781 of the FY2026 agriculture appropriations act (P.L. 119-37), which was set to tighten the legal definition of hemp products effective November 12, 2026. HR6209 would retroactively repeal that section, effectively restoring the 2018 Farm Bill's definition of hemp (cannabis with ≤0.3% delta-9 THC) for ALL hemp-derived products, including delta-8 THC and certain CBD extracts that were at risk of reclassification.
The bill authorizes zero dollars. It is a deregulatory repeal—no spending, no grants, no contracts. The money trail is purely regulatory: it prevents a scheduled tightening that would have narrowed the legal market for hemp-derived cannabinoids. The Congressional Budget Office would score this as reducing federal regulatory enforcement costs but generating no direct government spending.
The legislative path is weak. Five months after introduction, the bill remains in the House Committee on Agriculture with only 3 cosponsors (Mace, Massie, Lofgren, Baird). The 119th Congress is now well into its second session, and this bill has generated no additional action. Its primary sponsor is a junior member of the House (Rep. Mace). No companion bill exists in the Senate. The bill's passage probability is low in the current Congress.
Real market data from April 2026 shows cannabis-related stocks declining sharply: TLRY at $6.14 (7-day -11.53%, 52-wk range $3.50-$23.20), CGC at $1.09 (7-day -10.66%), SNDL at $1.32 (7-day -13.73%). These moves are consistent with broader market weakness, not legislative catalysts. The 30-day changes show mixed signals: CGC +26.74% (volatile small cap), TLRY +2.5%, SNDL +2.33%—these are not driven by HR6209's progress (none), but by company-specific factors and sector sentiment.
For investors: this bill is a low-probability event that would provide modest regulatory relief to hemp product companies. It has no direct revenue impact—its effect is avoiding a future negative regulatory shock. The tickers affected (TLRY, CGC, SNDL) have small U.S. hemp exposure relative to their total revenue. The most significant beneficiary would be hemp-specialty growers and processors not publicly listed in the U.S. (e.g., private CBD companies), not the multi-state operators whose primary business is high-THC cannabis.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Repeal of section 781 of P.L. 119-37, which would have reinstated federal controls on hemp products (e.g., moving some hemp extracts back toward controlled substance regulation). The bill restores the 2018 Farm Bill definition of hemp (≤0.3% delta-9 THC) for all hemp-derived products.
Who must act
Hemp cultivators, processors, and distributors—specifically companies in the U.S. hemp-derived cannabinoid supply chain relying on the 2018 Farm Bill's broad legal framework.
What happens
Prevents the November 12, 2026 scheduled tightening of federal regulatory controls on certain hemp derivatives (e.g., delta-8 THC, CBD extracts). Obligated parties avoid compliance costs, product bans, and market contraction that would have occurred under the new definition. The market for hemp-derived cannabinoids continues to operate under the current permissive federal baseline.
Stock impact
Tilray Brands' hemp segment (including Manitoba Harvest and its U.S. hemp beverage and CBD product lines) retains access to the broader legal market for hemp-derived cannabinoids. Avoided regulatory tightening preserves existing revenue streams from hemp-based foods, topicals, and extracts—estimated at low single-digit millions for Tilray's U.S. hemp business.
What the bill does
Same as above: repeal of the re-imposed federal controls on hemp products, restoring the 2018 Farm Bill definition for all hemp derivatives.
Who must act
U.S. hemp product manufacturers and distributors under federal jurisdiction.
What happens
Hemp-derived CBD and other cannabinoid product markets avoid a contraction scheduled for late 2026. Companies avoid sudden compliance costs, labeling restrictions, or ingredient prohibition tied to a narrower definition of legal hemp.
Stock impact
Canopy Growth's U.S. hemp strategy (mainly through BioSteel sports nutrition and its CBD wellness brand, Martha Stewart CBD) remains viable under the current legal framework. Avoided regulatory shock supports the segment's current revenue run rate. Canopy's core cannabis business is Canadian; hemp impact is modest relative to total revenue.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Hemp Planting Predictability Act
Proclamation: Imposing Additional Duties to Offset Canadian Discrimination Against the Commerce of the United States with Respect to Alcoholic Beverages
Proclamation: Imposing Additional Duties to Offset Canadian Discrimination Against the Commerce of the United States with Respect to Dairy
Proclamation: Restoring American Commercial Fishing in the Pacific
Proclamation: Further Adjusting the Tariff Regimes for Imports of Aluminum, Steel, and Copper into the United States
Executive Order: Advancing Regenerative Agriculture and Strengthening American Farm Resilience
Proclamation: Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
Proclamation: Imposing Additional Duties to Offset Canadian Discrimination Against the Commerce of the United States with Respect to Motor Vehicles
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Imposing Additional Duties to Offset Canadian Discrimination Against the Commerce of the United States with Respect to Motor Vehicles
This proclamation imposes a 50% ad valorem duty on certain Canadian products, effective August 19, 2026, under Section 338 of the Tariff Act of 1930, to offset Canada's discriminatory 25% tariff and tariff-rate quota on U.S. motor vehicle exports, which have reduced U.S. auto exports to Canada by 22% and shifted demand to competitors like Mexico, Japan, Korea, and Germany.
Imposing Additional Duties to Offset Canadian Discrimination Against the Commerce of the United States with Respect to Dairy
President Trump, citing Section 338 of the Tariff Act of 1930, imposes a 50% additional ad valorem duty on certain Canadian products (listed in Annex II) effective August 19, 2026, to offset Canada's discriminatory dairy tariff-rate quota allocation that disadvantages U.S. cheese exporters compared to EU exporters under CETA. The action aims to pressure Canada to remove the discrimination and expand opportunities for U.S. dairy producers within the U.S. market.
Imposing Additional Duties to Offset Canadian Discrimination Against the Commerce of the United States with Respect to Alcoholic Beverages
This proclamation imposes a 50% ad valorem duty on certain Canadian products under Section 338 of the Tariff Act of 1930, effective August 19, 2026, to retaliate against Canadian provincial bans on U.S. alcoholic beverages that have reduced U.S. exports by 81%. It directs the U.S. Trade Representative and Customs and Border Protection to implement the duties via the Harmonized Tariff Schedule, targeting a range of Canadian goods to offset the trade disadvantage.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →